Home / Healthcare / Coenzyme Q10 Market

Coenzyme Q10 Market Size, Share, and Industry Analysis By Type (Ubiquinone and Ubiquinol), By Application (Food Grade and Pharmaceutical Grade), By End-user (Food & Nutraceuticals Industry, Pharmaceutical Industry, and Others), and Regional Forecast 2024-2032

Report Format: PDF | Published Date: Ongoing | Report ID: FBI109346 | Status : Upcoming

Coenzyme Q10 Market is a fat-soluble compound found in all cellular membranes in the body. Coenzyme Q10 (CoQ10) is naturally present in diet and can also be produced in the human body. It plays a key role in transferring electrons in the mitochondria for the generation of cellular energy. Additionally, CoQ10 may enhance the production of major antioxidants such as superoxide dismutase to reduce oxidative stress and maintain homeostasis.


Coenzyme Q10 is classified as ubiquinone and ubiquinol on the basis of its molecular structure. Ubiquinone is an oxidized form of Coenzyme Q10 Market, and ubiquinol is a reduced form of it. The market for Coenzyme Q10 is anticipated to witness growth mainly due to an awareness of the benefits of Coenzyme Q10. The antioxidant properties and its ability to control cellular damage and enhance skin and overall health are some other key factors driving the growth of the market.


Furthermore, various clinical studies have shown a positive impact of Coenzyme Q10 on chronic conditions by reducing inflammation and oxidative stress in the body. The increasing incidences of chronic conditions such as diabetes, cardiovascular diseases, and cancer have led to a rise in the demand for Coenzyme Q10 supplements due to its proven ability to reduce inflammation and oxidative stress in the body, as demonstrated in the clinical studies.



  • For instance, a meta-analysis of twenty-one randomized clinical studies published in Frontiers Pharmacology in July 2022 stated that utilization of Coenzyme Q10, as an adjuvant treatment suppresses the oxidative stress in various conditions.


Moreover, the growth in the technological advancements of Coenzyme Q10 production, formulation, and delivery systems are also driving the market growth. However, the lack of approvals from regulatory agencies such as the U.S. FDA of these products for a specific indication may hamper the market growth.


The Coenzyme Q10 market witnessed a decline in growth at the beginning of the COVID-19 pandemic due to factors such as worldwide lockdowns, disruptions in supply chains, constraints in manufacturing resources, and other restrictions. These challenges impacted the market in early 2020, resulting in a slight decline in growth.


Later, a surge in the demand for immune-boosting supplements and antioxidants, including Coenzyme Q10, propelled the market growth. In addition, various product launches and the increasing consumption of antioxidants to maintain the homeostasis of immunity further led the industry expansion. In 2021, the market had grown substantially due to the surge in awareness of supplements containing Coenzyme Q10 and the significance of maintaining good health.


Key Insights


The report covers the following key insights:



  • Overview of Regulatory Scenario by Key Regions

  • Incidence and Prevalence of Cardiovascular Diseases, Key Countries, 2023

  • Key Industry Developments - Acquisitions, Partnerships, and Others

  • Impact of COVID-19 on the Market


Segmentation


















By Type



By Application



By End-user



By Geography




  • Ubiquinone

  • Ubiquinol




  • Food Grade

  • Pharmaceutical Grade




  • Food & Nutraceutical Industry

  • Pharmaceutical Industry

  • Others




  • North America (U.S. and Canada)

  • Europe (Germany, France, U.K., Italy, Spain, Scandinavia, and the Rest of Europe)

  • Asia Pacific (Japan, China, Australia, India, Southeast Asia, and the Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, and the Rest of Latin America)

  • Middle East & Africa (GCC, South Africa, and the Rest of the Middle East & Africa)



Analysis by Type


Based on type, the market is classified into ubiquinone and ubiquinol. The ubiquinone segment held a significant revenue share in the market. Ubiquinone is the most common form that is utilized in the supplements due to its stability. The increasing awareness of the importance of ubiquinone in maintaining the overall health is one of the primary reasons for the segmental growth. Furthermore, the surge in demand for supplements is expected to increase the adoption of ubiquinone supplements. Additionally, the wide availability of ubiquinone in the form of supplements, is expected to propel the ubiquinone segment significantly.


On the other hand, the ubiquinol segment is growing due to its higher efficiency and activity. Ubiquinol is a reduced form of Coenzyme Q10 which had higher bioavailability and antioxidant activity. Moreover, various ubiquinol fortified food products is anticipated to drive the segment growth.



  • For instance, in January 2021, KANEKA CORPORATION launched Watashi no Chikara Q10 Yogurt. The yogurt contains 100 mg of an active form of Coenzyme Q10, ubiquinol.


Regional Analysis


North America dominated the global Coenzyme Q10 market and is expected to continue its dominance over the projected years. The increasing number of patients suffering from chronic diseases, coupled with the rising number of patients consuming coenzyme, are the major factors driving the regional market growth. Furthermore, the region's focus on preventive medicine and increasing consumption of supplements are anticipated to drive market growth across the region. Moreover, the strategic initiatives such as acquisitions by market players anticipated to drive the regional growth in the near future.



  • For instance, in September 2023, Sanofi acquired the U.S. based company Qunol to strengthen its consumer health business. Qunol offers various health supplements, mainly Coenzyme Q10 and turmeric-based health supplements.


The Asia Pacific market is expected to witness faster growth during the forecast period. The key growth factor includes the presence of major players and their production capabilities. Furthermore, the high prevalence of cardiac & other chronic conditions and awareness of consuming antioxidant supplements are the factors contributing to the growth of the market.



  • According to the journal of geriatric cardiology article published in June 2023, approximately 330 million individuals in China are affected by cardiovascular diseases, including 13 million strokes, 11.39 million coronary heart disease, 8.9 million heart failure and 5 million pulmonary heart disease. Such instances and increasing awareness regarding antioxidants and its health benefits in the control of chronic diseases expected to propel the regional growth.


Key Players Covered


The report includes the profiles of Coenzyme Q10 market key players such as KANEKA CORPORATION, Fengchen Group Co., Ltd, Pharmavit, Alpspure Lifesciences Pvt. Ltd, and Tishcon Corporation.


Key Industry Developments



  • In July 2023, Boryung Consumer Healthcare, a subsidiary of Boryung, launched Q10 Max, soft gel dietary capsules. The product contains Coenzyme Q10 100 mg as a functional ingredient for the homeostasis of antioxidant activity.

  • In July 2023, Fortifeye, an eye care products company, launched Fortifeye Next Gen Zinc Free Macular Defense Capsules for optimal eye health. The capsules contain Coenzyme Q10 as a functional ingredient.

  • Global
  • 2023
  • 2019-2022
  • PRICE
  • $ 4850
    $ 5850
    $ 6850
    Pre Book

Healthcare Clients